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We developed and applied pharmacokinetic-pharmacodynamic (PK-PD) models to characterize in vitro
bacterial rate of killing as a function of ceftazidime concentrations over time. For PK-PD modeling, data
obtained during continuous and intermittent infusion of ceftazidime in Pseudomonas aeruginosa killing exper-
iments with an in vitro pharmacokinetic model were used. The basic PK-PD model was a maximum-effect
model which described the number of viable bacteria (N) as a function of the growth rate (l) and killing rate
(«) according to the equation dN/dt 5 {l 2 « z [Cg/(EC50
g 1 Cg)]} z N, where g is the Hill factor, C is the
concentration of antibiotic, and EC50 is the concentration of antibiotic at which 50% of the maximum effect is
obtained. Next, four different models with increasing complexity were analyzed by using the EDSIM program
(MediWare, Groningen, The Netherlands). These models incorporated either an adaptation rate factor and a
maximum number of bacteria (Nmax) factor or combinations of the two parameters. In addition, a two-
population model was evaluated. Model discrimination was by Akaike’s information criterion. The experimen-
tal data were best described by the model which included an Nmax term and a rate term for adaptation for a
period up to 36 h. The absolute values for maximal growth rate and killing rate in this model were different
from those in the original experiment, but net growth rates were comparable. It is concluded that the derived
models can describe bacterial growth and killing in the presence of antibiotic concentrations mimicking human
pharmacokinetics. Application of these models will eventually provide us with parameters which can be used
for further dosage optimization.
The most commonly used in vitro parameter to quantify the
activity of antibiotics against a certain bacterium is the MIC.
This parameter reflects the effect of exposure of a certain
inoculum size to a constant concentration of the antibiotic for
a period of 16 to 20 h (10). The disadvantage of the MIC,
however, is that this parameter does not take the pattern of
killing over time into account since an effect is measured at one
end point only. Alternatively, in vitro killing curves are used to
describe the time course of the antibacterial effect; in order to
find the important parameters describing the killing behavior
of the antibiotic over time, data can then be fit to pharmaco-
dynamic models (6–8, 11). For instance, killing rate constants
can be obtained by plotting the logarithm of the number of
CFU obtained at different antibiotic concentrations over time.
By comparing killing rate constants at these concentrations,
the killing behavior of the antibiotic can be characterized. By
using this approach, it has been shown that the killing of
bacteria by b-lactam antibiotics is relatively concentration in-
dependent at values well above the MIC, with maximal activity
at concentrations four to five times the MIC, and that it pro-
ceeds in time (12). Therefore, the pharmacodynamic parame-
ter most commonly used to describe killing behavior of b-lac-
tams is time above the MIC. Killing rate constants at
concentrations much higher than the MIC are more or less
similar.
Although widely employed to characterize the susceptibility
of a bacterium, these methods do not reflect the situation in
vivo, where the antibiotic concentration is subject to consider-
able fluctuation due to elimination and multiple dosing regi-
mens. In order to simulate in vivo conditions more closely,
several in vitro pharmacokinetic models that mimic human
pharmacokinetics during bacterial killing studies have been
developed (for examples, see references 1 and 9). To date,
however, the mathematical characterization of the pharmaco-
kinetic-pharmacodynamic (PK-PD) relationship has received
relatively little attention. In some approaches linear models
assuming exponential growth and killing rates were used. How-
ever, these models did not take the maximum number of bac-
teria (Nmax) at the end of the growth phase into account (14,
15). An interesting model was presented by Eandi and Cecina,
who in an exponential-growth-rate model incorporated a term
for bacterial adaptation to account for emergence of resistance
(3). Pharmacodynamic nonlinear models, such as the Hill or
sigmoid maximum-effect (Emax) model, which are frequently
used for other classes of drug, have not been as common for
antibiotics (11). Mattie and coworkers applied the sigmoid
Emax model to their data, but the antibiotic concentration-time
profile did not mimic in vivo pharmacokinetics. As a result the
integrated pharmacodynamic model used is fairly complicated
and cannot be easily incorporated in computer programs for
dosage regimen optimization (7, 8). Recently, an Emax model
was incorporated in computer software for clinical computa-
tions of bacterial growth and killing dynamics (5). By using
these models, it will be possible not only to gain insight on the
distribution of an antibiotic in the different compartments but
also to simulate the effect of the antibiotic on bacteria in these
compartments under different conditions and thereby to pre-
dict the outcome. To effectively use these models, however,
both the values of parameters and PK-PD models describing
kill and regrowth kinetics of bacteria during various dosing
regimens are needed.
In order to determine the parameters to be included in a
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PK-PD model to adequately describe the antibacterial behav-
ior of ceftazidime, we describe here the use of five different
models of increasing complexity. The data were obtained from
experiments using an in vitro pharmacokinetic model simulat-
ing human ceftazidime pharmacokinetics during continuous
and intermittent infusion for three different Pseudomonas
aeruginosa strains (9).
(Part of these results were presented at the 35th Interscience
Conference on Antimicrobial Agents and Chemotherapy, San
Francisco, Calif., September 1995.)
MATERIALS AND METHODS
Theory.When a pharmacological effect is observed immediately and is directly
related to the drug concentration, a linear model, an Emax model, or a sigmoid
Emax pharmacodynamic model can be applied to describe the relationship be-
tween concentration and effect. The most simple model is the linear nonsat-
urable model, in which the change in number of bacteria over time is defined as
the number of viable bacteria (N) as a function of the growth rate and killing rate
in relation to the concentration (14). For antibiotics, the basic premise of the
models used is that the response in the model as described by the measurement
of CFU over time is directly related to the various parameters in the model. One
important parameter incorporated in the models is an Emax parameter. There-
fore, our most simple model was the Emax model as recently described by Maire
et al. (5). The bacterial killing is assumed to be a result of growth and killing rates
and can be described with an exponential-growth model. The rate of change of
the response over time can be described by
dN
dt
5 Hl 2 ε z C gC g 1 EC 50g J z N (model 1)
where l represents the growth rate, ε represents the maximum killing rate, C
represents the concentration of antibiotic, EC50 represents the concentration of
the antibiotic at which 50% of the Emax is obtained, and g represents the Hill
coefficient. The Hill coefficient represents the steepness of the concentration-
effect curve. For b-lactam antibiotics, values for this factor are in the higher
range, indicating that the Emax is quickly reached. The larger the Hill coefficient,
the steeper the linear phase of the log concentration-effect curve. This is the
pharmacological explanation for the more time-dependent than concentration-
dependent killing behavior of b-lactams.
In the above-mentioned model, the growth rate is uncontrolled. However,
because of limitations of space, nutrients, and other factors, there should be an
Nmax to which the in vitro culture can grow during or after a certain amount of
time. During short experiments, such as those with killing curves of 6 h, the Nmax
is usually not an important factor, but in experiments of longer duration it is. The
Nmax parameter was incorporated in a second model as follows:
dN
dt
5 Hl z S1 2 NNmaxD z N 2 ε z C
g
C g 1 EC 50
g J z N
(model 2)
Another factor which has to be taken into account is emergence of resistance.
There are basically two mechanisms. The first is a gradual increase in resistance
over time. This can be accounted for by incorporating an adaptation rate (a)
term in the model as follows:
dN
dt
5 Hl z ~1 2 e2at! 2 ε z C gC g 1 EC 50g J z N (model 3)
If the Nmax parameter is included as well, a fourth model can be constructed:
dN
dt
5 Hl z ~1 2 e2at! z S1 2 NNmaxD z N 2 ε z C
g
C g 1 EC 50
g J z N
(model 4)
A second mechanism by which the emergence of resistant microorganisms can
be explained is by assuming the presence of small numbers of bacterial subpopu-
lations with different degrees of susceptibility in the primary inoculum. One
approach to describe emergence of resistance is to use a two-population model.
The two-population model does not contain the adaptation rate parameter, but
an Nmax parameter can be included. Since the MICs for emerging resistant
microorganisms can be measured during the experiments, these microorganisms
can be incorporated in a two-population model as a separate population. Model
5, therefore, is similar to model 2 but has two kinetic equations to account for the
rate of change in N for each of the two different bacterial populations over time
(subscripts are used to distinguish the parameters for the two populations).
dN
dt
5 Hl1 z S1 2 N1NmaxD z N1 2 ε1 z C
g
C g 1 EC 50
g J z N1 1
Hl2 z S1 2 N2NmaxD z N2 2 ε2 z C
g
C g 1 EC 50
g J z N2 (model 5)
It is useful to define the pharmacodynamic MIC (ZMIC) as the concentration
at which the bacterial population is stable, i.e., the special case of the bactericidal
curve where the killing rate equals the growth rate, i.e., dN/dt 5 0, and N is
constant over time. This enables one to compute the relation between the ZMIC
and the EC50 (2).
FIG. 1. Computer simulation of the bacterial growth-time curves. (A) Sim-
ulation without a term for the Nmax in the culture (model 1) and simulation with
an Nmax of 10 (model 2). The fixed values are a growth rate of 1 h21 and no
bacterial killing (maximum killing rate of 0). (B) Simulation representing the
influence of the adaptation rate (a) on bacterial growth-time curves by using
model 3. The values in the model for the adaptation rate varied from 0 to 100
h21. The fixed values are a growth rate of 1.0 h21 and no bacterial killing
(maximum killing rate of 0). (C) Simulation with a term for the adaptation rate
but without a term for the Nmax in the culture (model 3) and simulation with an
adaptation rate and an Nmax of 10 (model 4). Fixed values are a growth rate of
1.0 h21, no bacterial killing (maximum killing rate of 0), and an adaptation rate
of 0.1 h21.
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ZMIC 5 Sl z EC 50gε 2 l D
1
g
(1)
Strains, pharmacokinetics, and killing curves. The modeling was performed
with data obtained from P. aeruginosa killing experiments during continuous and
intermittent infusion of ceftazidime by using an in vitro pharmacokinetic model
as described previously (9). Briefly, a two-compartment in vitro model consisting
of one central compartment and several peripheral compartments consisting of
disposable dialyzer units (ST23; Baxter, Utrecht, The Netherlands) was used to
expose the bacteria in the peripheral compartments to changing antibiotic con-
centrations mimicking human pharmacokinetics. Three P. aeruginosa strains, P1,
P4, and P16, for which the MICs were 1, 4, and 16 mg/liter, respectively, were
exposed to concentrations of ceftazidime during continuous (300 mg/liter/day)
and intermittent (100 mg/liter every 8 h) infusion over 36 h in the in vitro
pharmacokinetic model. During continuous infusion, the steady-state concentra-
tion was around 20 mg/liter. Peak concentrations during intermittent infusion
were around 100 mg/liter, and trough concentrations were around 1 mg/liter (9).
PK-PD modeling. The differential equations for models 1 to 5 were used in the
EDSIM program (version 2.0; MediWare, Groningen, The Netherlands), which
is based on object-oriented modeling. With the program the user is able to create
any type of model by using three basic objects: inputs, compartments, and
connections. The differential equations are solved by numerical integration. The
method used here was the fourth-order Runga-Kutta method with adaptive step
size control. Before each modeling session, the pharmacokinetic parameter val-
ues for that specific experiment were estimated. These parameter estimates were
kept constant during the actual PK-PD modeling. Next, the data were fitted to
pharmacodynamic models 1 to 5 as described above with a log-weighted adjust-
ment. The N and EC50 were fixed at the actual values, whereas the growth rate,
maximum killing rate, adaptation rate, Hill coefficient, and Nmax were not fixed.
The Hill coefficient obtained in the initial computations was always higher than
5 to 10 and was therefore fixed in subsequent calculations, which further stabi-
lized the model. To determine which model performed best, coefficients of
determination (R2) were calculated. In addition, model discrimination was based
on Akaike’s information criterion (13) and the F test. As a further validation of
the model, data obtained during continuous infusion were fitted to an intermit-
tent-infusion model and vice versa.
RESULTS
Model simulations. In Fig. 1A a computer simulation of the
effect of the Nmax as a parameter in the model is shown. The
effects of different adaptation rates in the models are shown in
Fig. 1B. The influence of the adaptation rate and Nmax as
determined by computer simulation is summarized in Fig. 1C.
Model fitting. The results of the fitting are summarized in
Table 1. The mean R2 and the mean Akaike values of the fits
for the three P. aeruginosa strains obtained during the two
modes of ceftazidime administration with PK-PD models 1 to
4 are shown. With increasing complexity, i.e., with the incor-
poration of an Nmax term and a term for the adaptation rate,
the performance of the models improved. All more complex
models were significantly better at explaining the data than
simpler models (P ,0.001 for all comparisons; F test). The
most complex model (model 4) that included an Nmax term and
an adaptation rate term described the data best in terms of R2
and Akaike’s criterion. Table 2 summarizes the growth, maxi-
mum killing, and adaptation rates obtained by fitting the data
to model 4. Figure 2 shows typical simulations with model 4 for
each strain during ceftazidime administration by both modes.
From the figure several patterns can be observed: (i) for the P1
strain, the general pattern of the fitted curve is the same during
continuous infusion as during intermittent infusion; (ii) the
patterns of the P1 and P4 strains are comparable during con-
tinuous infusion but not during intermittent infusion; and (iii)
during intermittent infusion the P4 and P16 strains show typ-
ical regrowth phases, coinciding with ceftazidime concentra-
tions below the MIC. The data were not fitted better by using
a two-population model (model 5), except for those experi-
ments where resistant microorganisms did emerge during the
experiment; then the data were fitted better only for the P16
strain. However, the model was applicable only if the MICs
were set at an unrealistic, lower value than the actually mea-
sured MICs. In other words, with measured MICs for the
resistant strains, the model could not describe the data well. If,
however, the MIC for the resistant population was set two
twofold dilutions lower than the actually measured MIC, the
model could be used in some cases (results not shown).
DISCUSSION
In this study, we have developed PK-PD models to describe
data previously reported for P. aeruginosa strains exposed to
continuous and intermittent infusion of ceftazidime. Computer
simulation was applied to determine which parameters need to
TABLE 1. R2 and Akaike values for models of activity of ceftazidime against P. aeruginosa during infusiona
Model Mode of infusion
R2 for strainb
Akaike valuec
P1 P4 P16
1 Continuous ,0.1 ,0.1 0.23 (0.05–0.52) 124 (56–176)
Intermittent ,0.1 ,0.1 ,0.1 152 (122–183)
2 Continuous 0.36 (0.20–0.51) 0.62 (0.56–0.68) ,0.1 17 (22–36)
Intermittent 0.23 (0.15–0.30) 0.20 (0.12–0.24) 0.37 (0.33–0.40) 21 (4–40)
3 Continuous 0.77 (0.74–0.80) 0.62 (0.34–0.89) 0.89 (0.89–0.90) 66 (18–110)
Intermittent 0.41 (0.27–0.63) 0.42 (0.18–0.86) 0.76 (0.70–0.82) 113 (78–152)
4 Continuous 0.75 (0.55–0.88) 0.70 (0.57–0.83) 0.93 (0.92–0.94) 28 (229–16)
Intermittent 0.74 (0.70–0.79) 0.78 (0.72–0.87) 0.89 (0.89–0.90) 215 (228–21)
a Values are means (ranges).
b The numbers of experiments available for analysis were as follows: for P1, three; for P4, three (continuous infusion) and two (intermittent infusion); and for P16,
two. Values of ,0.1 indicate that data could not be fitted to the model.
c The numbers of experiments available for analysis were eight for continuous infusion and seven for intermittent infusion.
TABLE 2. Estimates of growth rate, maximum killing rate, and
adaptation rate during continuous and intermittent infusion
Mode of infusion Strain
Hourly ratea
Growth Maximum killing Adaptation
Continuous P1 4.15 (0.60) 2.13 (0.70) 0.11 (0.06)
P4 3.96 (0.01) 1.80 (0.15) 0.11 (0.01)
P16 7.38 (2.57) 5.34 (1.17) 0.15 (0.04)
Intermittent P1 5.59 (0.60) 3.79 (1.23) 0.22 (0.12)
P4 4.83 (0.26) 3.32 (0.54) 0.14 (0.03)
P16 2.42 (0.37) 1.96 (0.17) 0.07 (0.01)
a Parameter estimates are means (standard deviations). Values were obtained
by fitting to model 4 in vitro ceftazidime data for continuous and intermittent
infusion.
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be incorporated in such a model. The results indicate that the
data were best fitted to a PK-PD model that included a term
for the Nmax in the culture and a term for the adaptation rate.
The latter term is necessary to account for emergence of re-
sistance. A model without a term for the adaptation rate did
not describe the data adequately. The maximal growth and
killing rates obtained by fitting the experimental data were
higher than the rates normally observed. For instance, the
growth rate of strain P1 during continuous infusion was 4.15
h21. This would imply a doubling time of around 10 min.
Similarly, during intermittent infusion this value is around 8
min. It is, however, important to realize that values for the rate
terms in the models used are apparent values and maximum
rates and as such cannot be used for comparison with param-
eter values reported by other methods. Usually, these rate
constants are defined differently, e.g., as net rate constants
representing the difference between net growth with antibiotic
and growth without antibiotic (7, 8). In our models the net
killing is the resultant of the growth and killing rates and is
obtained by fitting the data without any constraint. The rates
do show some correlation in the final correlation matrix, which
indicates interdependence. When expressed as the difference
between the fitted growth and maximal killing rates, more
realistic values are obtained, which are in keeping with the net
rates as determined in the original experiment (9). Further-
more, it has to be emphasized that the killing rates as obtained
are maximum killing rates and that killing itself is not the same
at the different time points.
In in vitro experiments, after an initial decrease in CFU a
regrowth occurs. The reasons for the observed regrowth are
not fully understood (6–8). A pharmacological explanation
would be that adaptation is the result of a gradual increase in
the MIC for the bacteria. However, a model in which the EC50,
which can be regarded as an apparent MIC, was defined as a
function of the adaptation rate could not describe the data.
From equation 1, it can be seen that the relationship between
ZMIC and EC50 is rather complex. In order to deal with this
phenomenon we therefore modified the PK-PD model by in-
troducing a term for the adaptation rate related to the growth
rate as described by Eandi and Cecina (3). With this model we
were able to adequately describe our data by means of three
parameters (growth rate, maximum killing rate, and adaptation
rate).
Adaptation, on the other hand, may represent a small frac-
tion of the original bacterial population that is phenotypically
resistant. The model with terms for two populations gave in-
ferior results when the MICs for the resistant microorganisms
isolated during the experiment were applied in the model, or
no fit could be found. However, the fact that the use of lower
MICs in the PK-PD model yielded good results indicates that
this model may still be useful in some cases and that the way
the MICs were measured is not representative of the “true”
MIC present during the experiments. On the other hand, the
MICs for the emerging resistant strains did increase over time,
indicating that an adaptation rate more accurately describes
this phenomenon than does a two-population model.
The simulations with the fitted parameters show CFU-time
curves which are in agreement with the pharmacodynamic be-
havior of b-lactams. If, for b-lactam antibiotics, bacterial kill-
ing is related to the length of time the antibiotic remains above
a threshold value, e.g., the MIC as defined in the model, it
follows that the dosage regimen that maintains concentrations
well above this value will be better able to prevent regrowth of
the pathogen (12). During continuous infusion, the attained
concentration of ceftazidime was approximately 20 mg/liter
and the killing curves for the P. aeruginosa strains for which the
respective MICs were 1 and 4 mg/liter indeed appeared to be
quite similar (Fig. 2A and B). Also, the estimates of the pa-
rameter values for these experiments are within the same
range (Table 2). Similarly, the concentrations of ceftazidime
during intermittent infusion remained above the MIC for the
P1 strain, and this curve (Fig. 2D) shows the same pattern, as
the trough concentrations in these experiments were 1 to 2
mg/liter. For the P. aeruginosa strain for which the MIC was 4
mg/liter, the pattern of killing during intermittent infusion
appears to be different. At concentrations of ceftazidime below
the MIC, slight regrowth occurs (Fig. 2E). This is even more
accentuated for the P16 strain (Fig. 2F). When this strain is
subjected to continuous infusion of ceftazidime, initial growth
occurs until the MIC is reached (Fig. 2C). This clearly dem-
onstrates the clinical importance of a loading dose when ap-
plying continuous infusion.
The second important phenomenon which can be observed
with this curve is that adaptation appears to play an important
role. While during intermittent infusion at least some killing is
observed when concentrations are far above the MIC after
dosing, resistant strains appear earlier during continuous infu-
sion, while the adaptation rate is higher than it is during in-
termittent infusion (Table 2). This may have consequences for
therapy, since this means that during continuous infusion, con-
centrations should indeed be several times the MIC, at least
for P. aeruginosa.
We have chosen to model the data with the sigmoid Emax
model, as it gave a valid description of the relationship be-
tween antibiotic concentration and killing. However, we used
an empirical equation to account for changes in susceptibility
and for emergence of resistant bacterial subpopulations. It
would be of great interest to explore further this type of mod-
eling with emphasis on the underlying mechanisms, i.e., a more
mechanism-based description of changes in susceptibility, by
relating EC50s to traditional MICs (4, 9). Such PK-PD models
available in computer software will provide a further tool to
analyze antibiotic regimens and may present the future optimal
clinical index of therapeutic effectiveness (2).
We conclude that the derived models can describe bacterial
growth and killing in the presence of antibiotic concentrations
mimicking human pharmacokinetics. Application of these
models will eventually provide us with a rationale for the
proper selection of the optimal dose, mode of administration,
and duration of antibiotic therapy.
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